Ophthotech Corp. (OPHT)

1.34
0.03 2.29
NASDAQ
Prev Close 1.31
Open 1.33
Day Low/High 1.28 / 1.38
52 Wk Low/High 1.02 / 2.87
Volume 79.10K
Exchange NASDAQ
Shares Outstanding 41.27B
Market Cap 59.84M
Div & Yield N.A. (N.A)

Latest News

Ophthotech To Present At The Alliance For Regenerative Medicine's (ARM) 7th Annual Cell & Gene Therapy Investor Day

Ophthotech To Present At The Alliance For Regenerative Medicine's (ARM) 7th Annual Cell & Gene Therapy Investor Day

Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.

Ophthotech To Present At The Cowen And Company 39th Annual Health Care Conference

Ophthotech To Present At The Cowen And Company 39th Annual Health Care Conference

Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.

Ophthotech Reports Fourth Quarter And Full Year 2018 Financial And Operating Results

Ophthotech Reports Fourth Quarter And Full Year 2018 Financial And Operating Results

Ophthotech Corporation (Nasdaq: OPHT) today announced financial and operating results for the fourth quarter and full year ended December 31, 2018 and provided a business update.

Ophthotech Corporation To Report Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On Tuesday, February 26, 2019

Ophthotech Corporation To Report Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On Tuesday, February 26, 2019

Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its fourth quarter and full year 2018 financial and operating results on Tuesday, February 26, 2019.

Ophthotech Corporation To Present At The 37th Annual J.P. Morgan Healthcare Conference

Ophthotech Corporation To Present At The 37th Annual J.P. Morgan Healthcare Conference

Ophthotech Corporation (NASDAQ: OPHT) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 37th Annual J.

Ophthotech Announces The Addition Of Ophthalmic Industry Leader, Calvin (Cal) W. Roberts, M.D., To Its Board Of Directors

Ophthotech Announces The Addition Of Ophthalmic Industry Leader, Calvin (Cal) W. Roberts, M.D., To Its Board Of Directors

Ophthotech Corporation (NASDAQ: OPHT) announced today the election of Calvin (Cal) W.

Ophthotech Announces Results From Phase 2a Safety Trial Of Zimura® In Combination With Lucentis® In Wet Age-Related Macular Degeneration

Ophthotech Announces Results From Phase 2a Safety Trial Of Zimura® In Combination With Lucentis® In Wet Age-Related Macular Degeneration

Ophthotech Corporation (NASDAQ:OPHT) today announced the results from its Phase 2a safety trial of Zimura ® (avacincaptad pegol), the Company's complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD).

Ophthotech Reports Third Quarter 2018 Financial And Operating Results

Ophthotech Reports Third Quarter 2018 Financial And Operating Results

Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the third quarter ended September 30, 2018 and provided a business update.

Ophthotech Expands Gene Therapy Pipeline In Orphan Retinal Diseases With Exclusive Option For Novel Product Candidates To Treat Best Vitelliform Macular Dystrophy (Best Disease)

Ophthotech Expands Gene Therapy Pipeline In Orphan Retinal Diseases With Exclusive Option For Novel Product Candidates To Treat Best Vitelliform Macular Dystrophy (Best Disease)

Ophthotech Corporation (NASDAQ:OPHT) announced today that it has entered into an exclusive option agreement with the University of Pennsylvania (Penn) and the University of Florida Research Foundation (UFRF) for rights to negotiate to acquire an exclusive...

Ophthotech Expands Innovative Retinal Disease Pipeline With Acquisition Of Versant Ventures' Inception 4

Ophthotech Expands Innovative Retinal Disease Pipeline With Acquisition Of Versant Ventures' Inception 4

Ophthotech Corporation (NASDAQ: OPHT) announced today that it has acquired Inception 4, Inc.

Ophthotech Corporation To Report Third Quarter 2018 Financial Results And Host Conference Call On Wednesday, October 31, 2018

Ophthotech Corporation To Report Third Quarter 2018 Financial Results And Host Conference Call On Wednesday, October 31, 2018

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter 2018 financial and operating results on Wednesday, October 31, 2018.

Ophthotech Completes Patient Recruitment As Planned For Its Phase 2b Clinical Trial Of Zimura® Monotherapy For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration

Ophthotech Completes Patient Recruitment As Planned For Its Phase 2b Clinical Trial Of Zimura® Monotherapy For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration

Ophthotech Corporation (NASDAQ:OPHT) announced completion of patient recruitment for its Phase 2b clinical trial of Zimura ® (avacincaptad pegol), the Company's complement factor C5 inhibitor, monotherapy in patients with geographic atrophy secondary to...

Ophthotech Corporation To Present At Chardan's 2nd Annual Genetic Medicines Conference

Ophthotech Corporation To Present At Chardan's 2nd Annual Genetic Medicines Conference

Ophthotech Corporation (Nasdaq: OPHT) announced today that Keith Westby, Chief Operating Officer, will present an overview of the Company at Chardan's 2 nd Annual Genetic Medicines Conference, on Tuesday, October 9, 2018 at 8:30 a.

Scientific Data For Novel Adeno-Associated Virus Gene Therapy In Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published In Proceedings Of The National Academy Of Sciences

Scientific Data For Novel Adeno-Associated Virus Gene Therapy In Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published In Proceedings Of The National Academy Of Sciences

Ophthotech Corporation (NASDAQ: OPHT) announced today that scientists at the University of Pennsylvania (Penn) and University of Florida published proof-of-concept study results on an adeno-associated virus (AAV) gene therapy product candidate for the...

Ophthotech Reports Second Quarter 2018 Financial And Operating Results

Ophthotech Reports Second Quarter 2018 Financial And Operating Results

Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the second quarter ended June 30, 2018 and provided a business update.

Ophthotech Corporation To Report Second Quarter 2018 Financial Results And Host Conference Call On Wednesday, August 1, 2018

Ophthotech Corporation To Report Second Quarter 2018 Financial Results And Host Conference Call On Wednesday, August 1, 2018

Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its second quarter 2018 financial and operating results on Wednesday, August 1, 2018.

Ophthotech Enters Into Gene Therapy Agreements With The University Of Florida And The University Of Pennsylvania

Ophthotech Enters Into Gene Therapy Agreements With The University Of Florida And The University Of Pennsylvania

Ophthotech Corporation (NASDAQ: OPHT) announced today that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania (Penn) to develop and commercialize a novel...

Ophthotech Reports First Quarter 2018 Financial And Operating Results

Ophthotech Reports First Quarter 2018 Financial And Operating Results

Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the first quarter ended March 31, 2018 and provided a business update.

Ophthotech Completes Patient Recruitment In The Phase 2a Clinical Trial Of Zimura® In Combination With Anti-VEGF Therapy In Wet Age-Related Macular Degeneration

Ophthotech Completes Patient Recruitment In The Phase 2a Clinical Trial Of Zimura® In Combination With Anti-VEGF Therapy In Wet Age-Related Macular Degeneration

Ophthotech Corporation (NASDAQ: OPHT) today announced the completion of patient enrollment in its Phase 2a clinical trial of Zimura ® (avacincaptad pegol), the Company's complement factor C5 inhibitor, in patients with wet age-related macular...

Ophthotech Corporation To Report First Quarter 2018 Financial Results And Host Conference Call On Wednesday, May 9, 2018

Ophthotech Corporation To Report First Quarter 2018 Financial Results And Host Conference Call On Wednesday, May 9, 2018

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018.

Ophthotech To Present At The Cowen And Company 38th Annual Health Care Conference

Ophthotech To Present At The Cowen And Company 38th Annual Health Care Conference

Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GTLS, JWN, SBLK, SSW, VRTX Downgrades: ACU, AFH, BKS, CRAY, MATX, MEI, NYLD.A, OPHT Initiations: WAAS Read on to get TheStreet Quant Ratings' detailed report:

Ophthotech Reports Fourth Quarter And Full Year 2017 Financial And Operating Results

Ophthotech Reports Fourth Quarter And Full Year 2017 Financial And Operating Results

Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the fourth quarter and full year ended December 31, 2017 and provided a business update.

Ophthotech Targets Gene Therapy To Expand Its Orphan And Age-Related Retinal Disease Strategy

Ophthotech Targets Gene Therapy To Expand Its Orphan And Age-Related Retinal Disease Strategy

Ophthotech Corporation (NASDAQ:OPHT) announced today that the Company has initiated an innovative gene therapy research collaboration focused on applying novel gene therapy technology to discover and develop next-generation...

Ophthotech Corporation To Report Fourth Quarter And Full Year 2017 Financial Results And Host Conference Call On Tuesday, February 27, 2018

Ophthotech Corporation To Report Fourth Quarter And Full Year 2017 Financial Results And Host Conference Call On Tuesday, February 27, 2018

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its fourth quarter and full year 2017 financial and operating results on Tuesday, February 27, 2018.

Ophthotech Announces First Patient Enrolled In The Phase 2b Clinical Trial Of Zimura®, Complement C5 Inhibitor, For The Treatment Of Autosomal Recessive Stargardt Disease (STGD1)

Ophthotech Announces First Patient Enrolled In The Phase 2b Clinical Trial Of Zimura®, Complement C5 Inhibitor, For The Treatment Of Autosomal Recessive Stargardt Disease (STGD1)

Ophthotech Corporation (NASDAQ:OPHT) announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura ®...

Ophthotech Announces Election Of Jane Pritchett Henderson, Chief Financial Officer And Senior Vice President Of Corporate Development At Voyager Therapeutics, To Its Board Of Directors

Ophthotech Announces Election Of Jane Pritchett Henderson, Chief Financial Officer And Senior Vice President Of Corporate Development At Voyager Therapeutics, To Its Board Of Directors

Ophthotech Corporation (NASDAQ: OPHT) announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors,...